Skip to main content
Equibles
PACB logo

PACB · Pacific Biosciences Of California, Inc.

Track PACB — free

Use PACB with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PACB

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.15 +0.00 (+0.00%) At close · Aug 14
Market Cap
$357.46M
Shares
310.83M

Pacific Biosciences Of California, Inc. Earnings Call Transcripts

Every quarterly earnings call for Pacific Biosciences Of California, Inc. (PACB) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼7.4% $32.31M −$76.97M '22 Q3 22-10-26 ▼24.1% $27.35M −$84.38M '22 Q4 23-01-09 ▲17.3% $38.90M −$88.02M '23 Q1 23-05-02 ▲34.1% $47.57M −$69.83M '23 Q2 23-08-02 ▲72.4% $55.69M −$66.87M '23 Q3 23-10-30 ▲113.3% $58.36M −$82.02M '23 Q4 24-02-15 ▼0.2% $38.81M −$78.18M '24 Q1 24-05-09 ▼24.3% $36.01M −$173.32M '24 Q2 24-08-07 ▼28.2% $39.97M −$60.73M '24 Q3 24-11-07 ▼32.8% $39.22M $2.37M '24 Q4 25-02-13 ▼4.3% $37.15M −$426.07M '25 Q1 25-04-09 ▲10.4% $39.77M −$41.93M '25 Q2 25-08-07 ▼3.8% $38.44M −$38.00M '25 Q3 25-11-05 ▲13.8% $44.65M −$40.37M '25 Q4 26-02-12 ▲0.1% $37.18M −$8.28M '26 Q1 26-05-07 LATEST ▼1.9% $39.01M −$44.74M '26 Q2 26-08-05
Annual General Meeting
Investor event
2026-09-24
The 85th Annual Meeting of the Japanese Cancer Association
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Annual General Meeting
Investor event
2026-09-15
The 78th Annual Meeting of The Society for Biotechnology, Japan
Scheduled
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Pacific Biosciences Of California, Inc. Q2 FY2026 Earnings Call
Balanced tone HiFi platform and consumables Sparknext chemistry launch Clinical market growth
Revenue
$39.01M
▼ 1.9% YoY
Diluted EPS
$-0.14
Gross margin
32.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Pacific Biosciences Of California, Inc. Q1 FY2026 Earnings Call
Positive tone Consumables / Clinical Growth Vega Instruments Revio Installed Base
Revenue
$37.18M
▲ 0.1% YoY
Diluted EPS
$-0.03
Gross margin
34.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Pacific Biosciences Of California, Inc. Q4 FY2025 Earnings Call
Positive tone Instrument Placements (Revio and Vega) Consumables Growth and Clinical Adoption Gross Margin Expansion
Revenue
$44.65M*
▲ 13.8% YoY
Gross margin
37.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Pacific Biosciences Of California, Inc. Q3 FY2025 Earnings Call
Positive tone Revio System Clinical and HiFi Adoption Revenue and Guidance
Revenue
$38.44M
▼ 3.8% YoY
Diluted EPS
$-0.13
Gross margin
41.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Pacific Biosciences Of California, Inc. Q2 FY2025 Earnings Call
Positive tone Revenue and growth Revio placements and utilization Vega platform adoption
Revenue
$39.77M
▲ 10.4% YoY
Diluted EPS
$-0.14
Gross margin
36.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-09
Pacific Biosciences Of California, Inc. Q1 FY2025 Earnings Call
Cautious tone Product platforms: Revio, Vega, Spark, multi-use SMRT Cells Clinical and regional growth opportunities (EMEA, hospitals) Consumables growth and pull-through
Revenue
$37.15M
▼ 4.3% YoY
Diluted EPS
$-1.44
Gross margin
-3.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Pacific Biosciences Of California, Inc. Q4 FY2024 Earnings Call
Balanced tone Macroeconomic and NIH Funding Uncertainty Revio and Consumables Vega Benchtop Platform
Revenue
$39.22M*
▼ 32.8% YoY
Gross margin
25.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Pacific Biosciences Of California, Inc. Q3 FY2024 Earnings Call
Positive tone Product Launches (SPRQ/SpaRC, Vega) Revio Platform Adoption SoftBank Note Exchange / Balance Sheet
Revenue
$39.97M
▼ 28.2% YoY
Diluted EPS
$-0.22
Gross margin
25.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Pacific Biosciences Of California, Inc. Q2 FY2024 Earnings Call
Cautious tone Revio Instrument Demand Challenges Consumables and Revio Utilization Restructuring and Cost Reduction
Revenue
$36.01M
▼ 24.3% YoY
Diluted EPS
$-0.64
Gross margin
16.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Pacific Biosciences Of California, Inc. Q1 FY2024 Earnings Call
Cautious tone Revio instrument sales cycle elongation Cost reduction and margin improvement Long-term cash flow positive goal by 2026
Revenue
$38.81M
▼ 0.2% YoY
Diluted EPS
$-0.29
Gross margin
29.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Pacific Biosciences Of California, Inc. Q4 FY2023 Earnings Call
Positive tone Revio instrument adoption and installed base Onso short-read platform ramp Consumables pull-through and Revio utilization
Revenue
$58.36M*
▲ 113.3% YoY
Gross margin
16.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-30
Pacific Biosciences Of California, Inc. Q3 FY2023 Earnings Call
Revenue
$55.69M
▲ 72.4% YoY
Diluted EPS
$-0.26
Gross margin
32.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Pacific Biosciences Of California, Inc. Q2 FY2023 Earnings Call
Revenue
$47.57M
▲ 34.1% YoY
Diluted EPS
$-0.28
Gross margin
32.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Pacific Biosciences Of California, Inc. Q1 FY2023 Earnings Call
Revenue
$38.90M
▲ 17.3% YoY
Diluted EPS
$-0.36
Gross margin
25.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-09
Pacific Biosciences Of California, Inc. Q4 FY2022 Earnings Call
Revenue
$27.35M*
▼ 24.1% YoY
Gross margin
18.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-26
Pacific Biosciences Of California, Inc. Q3 FY2022 Earnings Call
Revenue
$32.31M
▼ 7.4% YoY
Diluted EPS
$-0.34
▼ 525% YoY
Gross margin
41.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Pacific Biosciences Of California, Inc. Q2 FY2022 Earnings Call
Revenue
$35.47M
▲ 15.9% YoY
Diluted EPS
$-0.32
Gross margin
45.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Pacific Biosciences Of California, Inc. Q1 FY2022 Earnings Call
Revenue
$33.17M
▲ 14.4% YoY
Diluted EPS
$-0.37
Gross margin
42.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
Pacific Biosciences Of California, Inc. Q4 FY2021 Earnings Call
Revenue
$36.02M*
▲ 43.3% YoY
Gross margin
46.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Pacific Biosciences Of California, Inc. Q3 FY2021 Earnings Call
Revenue
$34.89M
▲ 82.8% YoY
Diluted EPS
$0.08
Gross margin
44.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Pacific Biosciences Of California, Inc. Q2 FY2021 Earnings Call
Revenue
$30.61M
▲ 60.4% YoY
Diluted EPS
$-0.21
Gross margin
44.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Pacific Biosciences Of California, Inc. Q1 FY2021 Earnings Call
Revenue
$29.00M
▲ 85.9% YoY
Diluted EPS
$-0.45
▼ 4600% YoY
Gross margin
44.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Pacific Biosciences Of California, Inc. Q4 FY2020 Earnings Call
Revenue
$25.13M*
▼ 10% YoY
Gross margin
45.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Pacific Biosciences Of California, Inc. Q3 FY2020 Earnings Call
Revenue
$19.08M
▼ 12.9% YoY
Diluted EPS
$-0.14
Gross margin
37.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-03
Pacific Biosciences Of California, Inc. Q2 FY2020 Earnings Call
Revenue
$19.08M
▼ 22.5% YoY
Diluted EPS
$-0.15
Gross margin
34.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Pacific Biosciences Of California, Inc. Q1 FY2020 Earnings Call
Revenue
$15.60M
▼ 5% YoY
Diluted EPS
$0.01
Gross margin
48.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-06
Pacific Biosciences Of California, Inc. Q4 FY2019 Earnings Call
Revenue
$27.93M
▲ 43% YoY
Gross margin
46.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1299130 CUSIP 69404D108 13F (30d) 217 filings 212 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)